Candel Therapeutics/$CADL
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Candel Therapeutics
Candel Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing off-the-shelf viral immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. The immune cells induced by these viral immunotherapies are believed to target patients' specific tumor antigens, potentially improving responses in immunologically hot tumors while at the same time infiltrating the tumor microenvironment, transforming non-inflamed cold tumors with limited immune response into hot tumors. The company has established two clinical off-the-shelf viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.
Ticker
$CADL
Sector
Primary listing
Employees
55
Headquarters
Website
CADL Metrics
BasicAdvanced
$453m
-
-$0.72
-0.90
-
Price and volume
Market cap
$453m
Beta
-0.9
52-week high
$7.66
52-week low
$4.34
Average daily volume
1.5m
Financial strength
Current ratio
13.492
Quick ratio
13.308
Long term debt to equity
93.581
Total debt to equity
94.438
Interest coverage (TTM)
-22.74%
Profitability
EBITDA (TTM)
-47.331
Management effectiveness
Return on assets (TTM)
-25.95%
Return on equity (TTM)
-64.58%
Valuation
Price to book
6.53
Price to tangible book (TTM)
6.53
Price to free cash flow (TTM)
-8.414
Free cash flow yield (TTM)
-11.89%
Free cash flow per share (TTM)
-0.734
Growth
Earnings per share change (TTM)
-58.61%
3-year earnings per share growth (CAGR)
3.41%
CADL News
AllArticlesVideos
Candel Therapeutics teams up with EVERSANA to prep for prostate cancer drug launch
Proactive Investors·2 days ago
Candel Therapeutics Stock Soars After Cantor Fitzgerald's Overweight Rating
Benzinga·2 weeks ago
Candel Therapeutics reports extended survival in Phase 2a lung cancer trial of CAN-2409
Proactive Investors·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Candel Therapeutics stock?
Candel Therapeutics (CADL) has a market cap of $453M as of May 01, 2026.
What is the P/E ratio for Candel Therapeutics stock?
The price to earnings (P/E) ratio for Candel Therapeutics (CADL) stock is 0 as of May 01, 2026.
Does Candel Therapeutics stock pay dividends?
No, Candel Therapeutics (CADL) stock does not pay dividends to its shareholders as of May 01, 2026.
When is the next Candel Therapeutics dividend payment date?
Candel Therapeutics (CADL) stock does not pay dividends to its shareholders.
What is the beta indicator for Candel Therapeutics?
Candel Therapeutics (CADL) has a beta rating of -0.9. This means that it has an inverse relation to market volatility.